Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker
Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now